EasySep™ Human ILC2 Isolation Kit
Immunomagnetic positive selection kit using particle release technology
Overview
First, CRTH2+ cells are isolated by column-free immunomagnetic positive selection using antibody complexes and EasySep™ Releasable RapidSpheres™. Then, bound magnetic particles are removed from the EasySep™-isolated CRTH2+ cells, and unwanted non-ILC2s are targeted for depletion using antibody complexes and EasySep™ Dextran RapidSpheres™. The final isolated fraction contains highly purified ILC2s that are immediately ready for downstream applications.
Following cell isolation with this EasySep™ kit, antibody complexes remain bound to the cell surface and may interact with Brilliant Violet™ antibody conjugates, polyethylene glycol-modified proteins or other chemically related ligands.
Data Figures
Figure 1. Typical EasySep™ Human ILC2 Isolation Profile
Starting with fresh leukapheresis samples, the ILC2 content (CD45+Lin- CRTH2+CD161+CD127+) of the isolated fraction typically ranges from 84 - 95%. In the above example, the purities of the start and final isolated fractions are 0.03% and 91% (gated on CD45), respectively.
Protocols and Documentation
Find supporting information and directions for use in the Product Information Sheet or explore additional protocols below.
Applications
This product is designed for use in the following research area(s) as part of the highlighted workflow stage(s). Explore these workflows to learn more about the other products we offer to support each research area.
Resources and Publications
Educational Materials (9)
Quality Statement:
PRODUCTS ARE FOR RESEARCH USE ONLY AND NOT INTENDED FOR HUMAN OR ANIMAL DIAGNOSTIC OR THERAPEUTIC USES UNLESS OTHERWISE STATED. FOR ADDITIONAL INFORMATION ON QUALITY AT STEMCELL, REFER TO WWW.STEMCELL.COM/COMPLIANCE.
